CYTK Quote, Financials, Valuation and Earnings

Biogen has a net margin of -886.28% compared to Cytokinetics's net margin of 10.87%. Cytokinetics's return on equity of -- beat Biogen's return on equity of 10.33%.

Cytokinetics has a consensus price target of $77.19, signalling upside risk potential of 90.92%. On the other hand Biogen has an analysts' consensus of $190.50 which suggests that it could grow by 60.3%. Given that Cytokinetics has higher upside potential than Biogen, analysts believe Cytokinetics is more attractive than Biogen.

Cytokinetics has a beta of 0.938, which suggesting that the stock is 6.231% less volatile than S&P 500. In comparison Biogen has a beta of 0.057, suggesting its less volatile than the S&P 500 by 94.303%.

Cytokinetics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biogen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cytokinetics pays -- of its earnings as a dividend. Biogen pays out -- of its earnings as a dividend.

Cytokinetics quarterly revenues are $16.9M, which are smaller than Biogen quarterly revenues of $2.5B. Cytokinetics's net income of -$150M is lower than Biogen's net income of $266.7M. Notably, Cytokinetics's price-to-earnings ratio is -- while Biogen's PE ratio is 10.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cytokinetics is 244.55x versus 1.79x for Biogen. Usually stocks with elevated PS ratios are considered overvalued.

Bristol-Myers Squibb has a net margin of -886.28% compared to Cytokinetics's net margin of 21.93%. Cytokinetics's return on equity of -- beat Bristol-Myers Squibb's return on equity of 32.01%.

Cytokinetics has a consensus price target of $77.19, signalling upside risk potential of 90.92%. On the other hand Bristol-Myers Squibb has an analysts' consensus of $57.84 which suggests that it could grow by 20.75%. Given that Cytokinetics has higher upside potential than Bristol-Myers Squibb, analysts believe Cytokinetics is more attractive than Bristol-Myers Squibb.

Cytokinetics has a beta of 0.938, which suggesting that the stock is 6.231% less volatile than S&P 500. In comparison Bristol-Myers Squibb has a beta of 0.408, suggesting its less volatile than the S&P 500 by 59.151%.

Cytokinetics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bristol-Myers Squibb offers a yield of 5.09% to investors and pays a quarterly dividend of $0.62 per share. Cytokinetics pays -- of its earnings as a dividend. Bristol-Myers Squibb pays out -54.35% of its earnings as a dividend.

Cytokinetics quarterly revenues are $16.9M, which are smaller than Bristol-Myers Squibb quarterly revenues of $11.2B. Cytokinetics's net income of -$150M is lower than Bristol-Myers Squibb's net income of $2.5B. Notably, Cytokinetics's price-to-earnings ratio is -- while Bristol-Myers Squibb's PE ratio is 17.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cytokinetics is 244.55x versus 2.04x for Bristol-Myers Squibb. Usually stocks with elevated PS ratios are considered overvalued.

Edgewise Therapeutics has a net margin of -886.28% compared to Cytokinetics's net margin of --. Cytokinetics's return on equity of -- beat Edgewise Therapeutics's return on equity of --.

Cytokinetics has a consensus price target of $77.19, signalling upside risk potential of 90.92%. On the other hand Edgewise Therapeutics has an analysts' consensus of $42.78 which suggests that it could grow by 188.26%. Given that Edgewise Therapeutics has higher upside potential than Cytokinetics, analysts believe Edgewise Therapeutics is more attractive than Cytokinetics.

Cytokinetics has a beta of 0.938, which suggesting that the stock is 6.231% less volatile than S&P 500. In comparison Edgewise Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Cytokinetics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edgewise Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cytokinetics pays -- of its earnings as a dividend. Edgewise Therapeutics pays out -- of its earnings as a dividend.

Cytokinetics quarterly revenues are $16.9M, which are larger than Edgewise Therapeutics quarterly revenues of --. Cytokinetics's net income of -$150M is lower than Edgewise Therapeutics's net income of -$39.7M. Notably, Cytokinetics's price-to-earnings ratio is -- while Edgewise Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cytokinetics is 244.55x versus -- for Edgewise Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Sage Therapeutics has a net margin of -886.28% compared to Cytokinetics's net margin of -747.33%. Cytokinetics's return on equity of -- beat Sage Therapeutics's return on equity of -63.59%.

Cytokinetics has a consensus price target of $77.19, signalling upside risk potential of 90.92%. On the other hand Sage Therapeutics has an analysts' consensus of $8.10 which suggests that it could grow by 4%. Given that Cytokinetics has higher upside potential than Sage Therapeutics, analysts believe Cytokinetics is more attractive than Sage Therapeutics.

Cytokinetics has a beta of 0.938, which suggesting that the stock is 6.231% less volatile than S&P 500. In comparison Sage Therapeutics has a beta of 0.477, suggesting its less volatile than the S&P 500 by 52.304%.

Cytokinetics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sage Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cytokinetics pays -- of its earnings as a dividend. Sage Therapeutics pays out -- of its earnings as a dividend.

Cytokinetics quarterly revenues are $16.9M, which are larger than Sage Therapeutics quarterly revenues of $12.8M. Cytokinetics's net income of -$150M is lower than Sage Therapeutics's net income of -$95.8M. Notably, Cytokinetics's price-to-earnings ratio is -- while Sage Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cytokinetics is 244.55x versus 11.48x for Sage Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.